Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sonnet BioTherapeutics Holdings, Inc.

3.92
-0.2300-5.54%
Post-market: 4.480.5600+14.29%16:59 EDT
Volume:6.20M
Turnover:23.07M
Market Cap:12.41M
PE:-0.55
High:4.14
Open:3.65
Low:3.10
Close:4.15
Loading ...

BRIEF-Sonnet Biotherapeutics Appoints Stephen Mcandrew As Chief Business Officer

Reuters
·
13 Feb

Sonnet Biotherapeutics Appoints Stephen Mcandrew, Ph.d. as Chief Business Officer

THOMSON REUTERS
·
13 Feb

Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer

GlobeNewswire
·
13 Feb

Sonnet BioTherapeutics Q1 EPS $(1.56) Misses $(1.39) Estimate

Benzinga
·
13 Feb

Sonnet Biotherapeutics Holdings Inc Qtrly Loss per Share $1.56

THOMSON REUTERS
·
13 Feb

Sonnet Biotherapeutics Holdings Inc: Jay Cross Resigns as CFO, Effective Feb 21, 2025

THOMSON REUTERS
·
13 Feb

Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update

GlobeNewswire
·
13 Feb

Sonnet Biotherapeutics Holdings Inc expected to post a loss of $1.39 a share - Earnings Preview

Reuters
·
10 Feb

BRIEF-Sonnet Biotherapeutics Further Expands Global Intellectual Property Portfolio With Issuance Of EU Patent For Fhab® Platform Technology

Reuters
·
29 Jan

Sonnet BioTherapeutics further expands global IP portfolio

TIPRANKS
·
28 Jan

Sonnet Biotherapeutics Further Expands Global Intellectual Property Portfolio With Issuance of EU Patent for Fhab® Platform Technology

THOMSON REUTERS
·
28 Jan

Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology

GlobeNewswire
·
28 Jan

BRIEF-Sonnet Biotherapeutics Files For Offering Of Up To 2 Million Shares Of Common Stock

Reuters
·
23 Jan

Sonnet Biotherapeutics Holdings Inc Files for Offering of up to 2.0 Mln Shares of Common Stock by the Selling Securityholder - SEC Filing

THOMSON REUTERS
·
23 Jan

Sonnet BioTherapeutics expands Phase 1 SB101 trial

TIPRANKS
·
21 Jan

Sonnet Biotherapeutics Holdings Inc - Topline Safety Data Expected in H2 2025

THOMSON REUTERS
·
21 Jan

Sonnet Biotherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of Son-1010 With Trabectedin in Certain Sarcomas

THOMSON REUTERS
·
21 Jan

Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas

GlobeNewswire
·
21 Jan

Sonnet Biotherapeutics Files Prospectus Related to Potential Offer, Sale From Time to Time by Chardan Capital Markets Llc of up to 625,000 Shares of Common Stock

THOMSON REUTERS
·
21 Jan